On the stock market since 2015, it operates in the world of health and science. It has 5,500 employees. Now — the numbers.
This is an established company with proven profits.
An average decline of 6% a year over the last 4 years — the most striking risk in this picture.
The gap is $2.2B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 42% below its peak. The market has trimmed its expectations for the company.
It pays out $0.01 per share each year — regular cash for whoever holds the stock.
The stock sits at $0.40. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 3 years, sales fell about 13% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
On our five-subject report card, LJUIF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: LJUIF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.